The vaccines were well tolerated in clinical trials, but failed to produce an adequate immune response.Visit Business Insider's homepage for more storiesUS pharma giant Merck has scrapped two coronavirus vaccine candidates after they failed to produce an adequate immune response in early trials, theThe vaccines were generally well tolerated, but worked less well than existing COVID-19 vaccines and immunity from catching the virus, Merck said in the press release.
The results were "disappointing, and a bit of a surprise," Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories,The studies haven't yet been published in a peer-reviewed journal to be scrutinized. Merck said it would now focus on advancing two experimental treatments for COVID-19 that are in late stage development.
"In the world of pharmaceutical development, a quick kill is not a bad thing because it allows you to reposition and repurpose your assets," Kartsonis
plz investigate ivermectin as a treatment...